Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis

M W Büchler, M Binder, H Friess

Abstract
Acute pancreatitis is caused by the activation of digestive enzymes in the pancreas and a possible treatment, therefore, is the inhibition of enzyme secretion. This approach is somewhat controversial, however, as it is not clear whether pancreatic secretion continues to occur during the course of acute pancreatitis. Animal studies show an appreciable reduction of secretion in the inflamed pancreas, but studies in humans are not conclusive. The use of somatostatin or its analogue, octreotide, has been investigated in several clinical studies. A meta analysis of six individual studies in which somatostatin was given for acute pancreatitis showed that somatostatin significantly reduces mortality. A trial in patients with moderate to severe acute pancreatitis showed a lower rate (although not statistically significant) of complications in patients treated with 3×200 and 3×500 µg/day octreotide, compared with controls and patients receiving a lower dose of octreotide. A further study showed a significant reduction in patient controlled analgesics in patients treated with octreotide compared with controls. Pain is the important clinical symptom of chronic pancreatitis, possibly resulting from an increased intraductal pressure during secretion. The effect on pain of the inhibition of pancreatic secretion by octreotide has been investigated in two studies. One showed no significant reduction in pain after treatment with octreotide for three days. In the other, in which octreotide was used for three weeks, significantly less pain and analgesic use was recorded during octreotide treatment than during placebo. The most common complication of chronic pancreatitis is the formation of pseudocysts. There is some evidence that octreotide may be useful in their treatment.

Somatostatin in acute pancreatitis
Acute interstitial pancreatitis is a mild and self limiting disease that responds well to conservative treatment. Therefore, it is associated with low complication and death rates. Ten to 20% of all patients with acute pancreatitis, however, develop peripancreatic and intrapancreatic necrosis. The release of toxic and vasoactive substances may lead to major systemic and metabolic complications followed by organ failure and death.

At present, there is no specific and effective treatment available for acute pancreatitis. Therefore, treatment, especially of acute necrotising pancreatitis, consists of symptomatic treatment in an intensive care unit. The lack of specific treatment for acute pancreatitis is possibly one explanation why the death rates associated with severe acute necrotising pancreatitis are still high (10–30%).

RATIONALE BEHIND THE INHIBITION OF PANCREATIC SECRETION IN PATIENTS WITH ACUTE PANCREATITIS
The pathogenic principle of acute pancreatitis is autodigestion, which is caused by the activation of digestive enzymes in the pancreas. Therefore, one therapeutic concept for the treatment of acute pancreatitis is the inhibition of exocrine pancreatic enzyme secretion to slow down autodigestion of the pancreatic parenchyma. Before secretion inhibiting substances are adopted as a treatment for acute pancreatitis, however, it must be established whether pancreatic secretion still takes place during the course of this condition.

EXOCRINE PancreATIC SECRETION DURING ACUTE PanCREATITIS
In animal studies using various pancreatitis models it has been shown that basal and stimulated pancreatic secretion is reduced in rats or mice with acute pancreatitis. Data on secretion in the human pancreas during the inflammatory phase of acute pancreatitis are scarce.

Regan et al. found increased pancreatic secretion of lipase and trypsin in two of three patients with acute pancreatitis who were seen in a clinical study on cimetidine and glucagon. Recently, we have reported that in six patients with mild or moderate acute pancreatitis, basal pancreatic secretion is similar to that in healthy subjects.

After an attack of acute pancreatitis, the secretory capacity of the pancreas becomes temporarily insufficient. The degree of pancreatic insufficiency depends on the severity of the inflammatory process in the pancreas. It is, however, not known at what point during the course of acute pancreatitis this insufficiency occurs, and further studies are necessary to answer this important question.

In cases of acute pancreatitis after pancreatic transplantation, which might possibly be considered a model to study acute pancreatitis
in humans, exocrine pancreatic function has been shown to be dependent on the degree of severity of the pancreatic inflammation.\textsuperscript{16} The more severe the transplantation pancreatitis, the less pancreatic secretion was present.

It is known that normal or food induced endogenous stimulation of the pancreas during inflammation worsens the course of acute pancreatitis and is absolutely contraindicated. In the basic treatment of the disease, endogenous stimulation is prevented by oral alimentary abstinence and continuous nasogastric suction.\textsuperscript{7} It is still controversial, however, whether basic treatment of acute pancreatitis should include the administration of secretion inhibiting substances. In a number of animal studies\textsuperscript{15-22} the effect of somatostatin and octreotide on the course of acute pancreatitis was investigated. There were some differences in both the experimental set up and the results of these studies. As some of the investigators gave secretion inhibiting substances before induction of acute pancreatitis and as secretion patterns during acute pancreatitis seem to differ between animals and humans, the results should not be transferred to the human situation.\textsuperscript{24}

The pathophysiological prerequisites for the use of secretion inhibiting substances for acute pancreatitis have not been fully clarified. Animal data showed a considerable reduction of secretion of the injured pancreas.\textsuperscript{10,11} The studies of human pancreatitis showed normal secretion function,\textsuperscript{13} whereas in transplantation pancreatitis, the amount of secretion depends on the degree of severity of the pancreatitis.\textsuperscript{18} There have been too few human studies, however, to permit any conclusions to be drawn. This controversial situation surely warrants putting the treatment principle 'inhibition of pancreatic secretion' to the clinical test.

### CLINICAL STUDIES WITH SOMATOSTATIN IN ACUTE PANCREATITIS

Clinical studies with secretion inhibiting substances such as glucagon, calcitonin, and atropine\textsuperscript{25-28} and studies with protease inhibitors like aprontin and gabexate mesilate,\textsuperscript{29,29} showed no positive effect on the course of acute pancreatitis.

### OCTREOTIDE IN ACUTE PANCREATITIS

We evaluated the effect of octreotide on the course of severe pancreatitis in an open prospective phase I/II study. Only patients with moderate to severe pancreatitis were included in the study. After randomisation eight patients in each group were treated either with $3 \times 100 \mu g$/day, $3 \times 200 \mu g$/day or $3 \times 500 \mu g$/day octreotide subcutaneously for 10 days. Complications were assessed according to a standard scoring system\textsuperscript{29} (Table II) on admission to hospital and in the follow up within 30 days.

A positive difference between the admission score and the follow up score was regarded as a positive treatment effect. A total of 24 patients (10 male, 14 female, median age 58 years, median Ranson score 3:4) were treated with octreotide. One hundred and eight patients with acute pancreatitis (median Ranson score 3:7) served as a historic control group.\textsuperscript{29} The three octreotide groups and the control group were comparable with regard to age, sex, and severity of pancreatitis. Two (8-3\%) of the octreotide treated patients died because of

### TABLE I  Score system in patients with acute pancreatitis.

<table>
<thead>
<tr>
<th>Organismic complications</th>
<th>Shock</th>
<th>Sepsis</th>
<th>Pulmonary insufficiency</th>
<th>Renal insufficiency</th>
<th>Peritonitis</th>
<th>Haemorrhage</th>
<th>Ileus/subileus</th>
<th>Metabolic complications</th>
<th>Hypocalcaemia</th>
<th>Enteropathy</th>
<th>Metabolic acidosis</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score (n)</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Notes:**
- The first clinical study in which somatostatin was used for acute pancreatitis was published by Limberg and Kommerell in 1980.\textsuperscript{30} In a study of 14 patients they found 'an impressive clinical improvement in all patients'. This promising finding was tested in several controlled clinical studies.\textsuperscript{31-34} Although the patients treated with somatostatin showed a lower complication rate, death rate, and better biochemical parameters, statistical significance could not be established. In a meta-analysis\textsuperscript{35} Carballo analysed the statistical quality of six randomised studies in which somatostatin was given for acute pancreatitis (Table I). In the six individual studies no statistically significant effect on mortality could be proved. The meta analysis showed that, taking these six studies together, somatostatin significantly reduces the mortality associated with acute pancreatitis ($p<0.01$, Table I). Further prospective studies with somatostatin or its analogues are necessary,\textsuperscript{36} using sufficient numbers of patients.
Octreotide in acute and chronic pancreatitis

There was a lower rate of complications in the groups treated with 3×200 and 3×500 μg/day octreotide than in the low dose octreotide and control groups (Table III). Because of the small number of patients the results have no statistical power.

In a further controlled study, 19 patients with acute pancreatitis were either treated with octreotide (250 μg subcutaneously, followed by 0.5 μg/kg/hour) or acted as controls. A significant reduction of the patient controlled consumption of analgesics was seen in octreotide treated patients compared with the controls (p < 0.05). Unfortunately, only patients with mild pancreatitis were admitted to this study, so that no conclusion can be made as to the differences in mortality between the octreotide and control groups. The possible analgesic effect of somatostatin in human acute pancreatitis has been confirmed in an Italian multicentre study.

**Perspectives**

The mechanism by which somatostatin and its analogue octreotide act on acute pancreatitis has been considered to be inhibition of exocrine pancreatic function. Another explanation stems from the notion of a 'cytoprotective' effect of these substances. Schwedes et al. induced acute pancreatitis in dogs by injecting bile into the ductal system and found considerably less macroscopic and histological damage to the pancreas in animals treated with somatostatin than in the control group. The inhibitory effect of somatostatin on pancreatic secretion could not, however, be solely responsible for these differences. The authors assumed that somatostatin had a further direct protective effect on the pancreatic acinar cells.

In a double blind randomised clinical study, Choi et al. saw a 'beneficial local effect' of somatostatin and that 'local inflammation was suppressed by somatostatin treatment'. Jenkins et al. studied the effect of somatostatin and octreotide on the reticuloendothelial system in rats with acute pancreatitis and recorded increased hepatic and splenic reticuloendothelial system activity. Furthermore, octreotide was shown to significantly reduce endotoxin concentrations in the serum. In patients with cirrhosis of the liver and portal hypertension octreotide increased the phagocyte activity of the monocytes. According to Jenkins et al. these results confirmed the cytoprotective effect of somatostatin and octreotide, which was originally postulated by Zsabo and Usadel. Overall the cytoprotective effect of octreotide seems to be a new and interesting feature in inflammatory disorders. Further studies are necessary to investigate the influence of this effect in acute pancreatitis.

To date, no conclusive evidence is available for or against the use of somatostatin or octreotide in acute pancreatitis. The efficacy of somatostatin or octreotide can only be proved in clinical studies. The results of a randomised, controlled multicentre trial with a study population of 300 patients, which is currently being started, will provide useful information on the future use of these substances for medical treatment of acute pancreatitis.

**Chronic pancreatitis**

Chronic pancreatitis is defined as the irreversible focal, segmental, or diffuse destruction of the pancreatic parenchyma. Four hypothetical concepts have been posed to explain the pathogenic mechanisms of chronic pancreatitis.

According to Sarles, the chronic intake of alcohol, which is the most important aetiological factor of chronic pancreatitis, causes a change in pancreatic secretion with the formation of protein plugs and calcifications in the ductal system of the pancreas. A second hypothesis is based on the notion of spontaneous activation of intraparenchymal proteases, which leads to small areas of pancreatic necrosis followed by fibrosis.

Furthermore, oxidative stress caused by increased levels of free radicals and disorders in hepatic detoxification and direct toxic effects of ethanol on pancreatic acinar and ductal cells are considered to play an important part in the pathophysiology of chronic pancreatitis.

**Table III** Results of a unicentric prospective trial analysing the effect of three different doses of octreotide in patients with moderate to severe acute pancreatitis. The sum of acute pancreatitis relevant complications was calculated according to the definition in Table II on admission to the hospital and in the follow up within 30 days. A positive difference represents a reduction of complications.

<table>
<thead>
<tr>
<th></th>
<th>Admission</th>
<th>Follow up</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5-1</td>
<td>7-2</td>
<td>-2-1</td>
</tr>
<tr>
<td>3×100 μg</td>
<td>5-6</td>
<td>7-1</td>
<td>-1-5</td>
</tr>
<tr>
<td>3×200 μg</td>
<td>5-0</td>
<td>2-0</td>
<td>+3-0</td>
</tr>
<tr>
<td>3×500 μg</td>
<td>5-8</td>
<td>4-8</td>
<td>+1-0</td>
</tr>
</tbody>
</table>
TABLE IV  Symptoms and complications in 223 patients with chronic pancreatitis

<table>
<thead>
<tr>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain 90</td>
</tr>
<tr>
<td>Pancreatic insufficiency 19</td>
</tr>
<tr>
<td>Diabetes mellitus 17</td>
</tr>
<tr>
<td>Insulin dependent 17</td>
</tr>
<tr>
<td>Non-insulin dependent 20</td>
</tr>
<tr>
<td>Pseudocysts &lt;6 cm 43</td>
</tr>
<tr>
<td>&gt;6 cm 12</td>
</tr>
<tr>
<td>Ascites 3</td>
</tr>
<tr>
<td>Stenosis of duodenum 6</td>
</tr>
<tr>
<td>Portal hypertension 4</td>
</tr>
</tbody>
</table>

The most recent classification of chronic pancreatitis distinguishes between four groups: (a) lithogenic pancreatitis, the largest group, which consists of five subgroups according to the type of stone; (b) obstructive pancreatitis, which is caused by obstruction of the pancreatic ducts before the onset of pancreatitis; (c) inflammatory pancreatitis; (d) pancreatic fibrosis.

Pain, either intermittent or persistent, is the major clinical symptom of chronic pancreatitis, even in the early stage of the disease. As the disease progresses, the characteristic triad of symptoms develops with pain, malabsorption, and diabetes mellitus. Roughly 40% of patients with chronic pancreatitis develop complications (Table IV).

Treatment for chronic pancreatitis includes: elimination of the cause; alcohol abuse; treatment of pain; treatment of pancreatic insufficiency; treatment of complications.

MANAGEMENT OF PAIN ASSOCIATED WITH CHRONIC PANCREATITIS BY OCTREOTIDE

Analgesics are usually indispensable in the treatment of the pain associated with chronic pancreatitis, although the possible polytoxicomania in these patients makes their use undesirable. An alternative method of pain treatment is based on the theory that pain may result from increased intraductal pressure during stimulation of pancreatic secretion. Therefore, the inhibition of pancreatic secretion should influence the chronic pain syndrome in patients with chronic pancreatitis. Enzyme substances given in high doses improves exocrine pancreatic insufficiency and reduces the pain in some patients, presumably as a result of feedback regulation.

The effect of direct inhibition of pancreatic secretion on pain associated with chronic pancreatitis was investigated in two independent studies. Malfertheiner et al. in a double blind randomised crossover study of 10 patients investigated the influence of 3x250 μg/day subcutaneously octreotide on pain. All patients received either octreotide treatment or placebo for three days in random order at two day intervals. The investigators saw no significant pain reduction after octreotide.

Another study group conducted a similar investigation in six patients with chronic pancreatitis and recurrent abdominal pain. The patients received 3x100 μg/day subcutaneously octreotide for three weeks and placebo for one week. During the octreotide treatment there was less pain and analgesic use recorded than during treatment with placebo (p<0.05). The authors concluded that octreotide provides relief of chronic abdominal pain associated with chronic pancreatitis in some, but not in all patients.

The discrepancy in these two clinical studies is difficult to explain. It might be that the different treatment times (three days compared with three weeks) had an effect on the success of the treatment. The results of a multicentre study carried out in the US, which should soon be available, are expected to provide further information on the use of octreotide to treat pain associated with chronic pancreatitis.

TREATMENT OF COMPLICATIONS ASSOCIATED WITH CHRONIC PANCREATITIS

The most common complication associated with chronic pancreatitis is the formation of intra or extrapancreatic pseudocysts. Small pseudocysts (2-6 cm) usually produce no clinical symptoms, while larger cysts (>6 cm) are often very painful and can cause haemorrhage, abscess, stenosis of the pancreatic duct, and bile duct obstruction, as well as stenosis of the duodenum. Various authors have pointed out the beneficial effect of octreotide in the treatment of pancreatic pseudocysts.

Gullo and Barbara treated seven patients with chronic pancreatitis who had developed pancreatic pseudocysts with 3x100 μg/day octreotide for two weeks. Four of seven patients responded immediately to the octreotide treatment and the mean size of the pseudocysts decreased by 42%. Furthermore, all four patients were completely pain free.

Morali et al. reported on an infected pancreatic pseudocyst in which percutaneous evacuation was not successful. After one week of treatment with 300 μg/day octreotide, the cyst shrunk from 8 cm to 1 cm and drainage secretion decreased from 200 ml/day to 30 ml/day. Similar results in the treatment of pancreatic pseudocysts that had persisted after percutaneous drainage were reported by Barkin et al. in a total of three patients.

In some cases, octreotide has also been reported to successfully treat ascites resulting from pancreatic disorders.

PERSPECTIVES

The new approach to the treatment of complications associated with chronic pancreatitis by somatostatin analogues is encouraging. Octreotide, a potent inhibitor of exocrine basal and stimulated pancreatic secretion, has been successfully used to prevent postoperative complications after pancreatic surgery and to treat pancreatic fistulae. The treatment of pancreatic pseudocysts and ascites with octreotide is the logical extension of this management concept.

Further studies are required, however, to find out if octreotide or the combination of percutaneous catheter drainage and octreotide treatment can reduce the rate of surgery necessary for symptomatic pseudocysts.
It has been suggested that the damaged pancreas reacts less effectively to the inhibitory effect of somatostatin on pancreatic exocrine secretion.\(^2\) The positive results,\(^2,25\) however, of octreotide in patients with chronic pancreatitis show that secretion inhibiting substances may be a new treatment concept in such patients.

14. Figure 10. Bar chart showing the results of the trial.
15. Figure 11. Graph illustrating the time course of serum amylase levels.
16. Table 1: Summary of patient characteristics.
17. Table 2: Comparison of clinical outcomes.
18. Table 3: Laboratory parameters at baseline and follow-up.
19. References: